DK2097444T3 - Fremgangsmåde, der anvender et transgent dyr med forøget immunrespons - Google Patents

Fremgangsmåde, der anvender et transgent dyr med forøget immunrespons

Info

Publication number
DK2097444T3
DK2097444T3 DK07859364.7T DK07859364T DK2097444T3 DK 2097444 T3 DK2097444 T3 DK 2097444T3 DK 07859364 T DK07859364 T DK 07859364T DK 2097444 T3 DK2097444 T3 DK 2097444T3
Authority
DK
Denmark
Prior art keywords
immune response
enhanced
animal
human animal
transgenic animal
Prior art date
Application number
DK07859364.7T
Other languages
English (en)
Inventor
Zsuzsanna Boesze
Imre Kacskovics
Judit Cervenak
Laszlo Hiripi
Balazs Bender
Original Assignee
Agricultural Biotechnology Ct
Eoetvoes Lorand University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2097444(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from HUE06000870 external-priority patent/HU0600870D0/hu
Application filed by Agricultural Biotechnology Ct, Eoetvoes Lorand University filed Critical Agricultural Biotechnology Ct
Application granted granted Critical
Publication of DK2097444T3 publication Critical patent/DK2097444T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07859364.7T 2006-11-24 2007-11-23 Fremgangsmåde, der anvender et transgent dyr med forøget immunrespons DK2097444T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUE06000870 HU0600870D0 (en) 2006-11-24 2006-11-24 Transgenic animal with increased immunoglobulin level and method for the preparation thereof
HUE07000534 2007-08-14
PCT/IB2007/054770 WO2008062383A2 (en) 2006-11-24 2007-11-23 Transgenic animal with enhanced immune response and method for the preparation thereof

Publications (1)

Publication Number Publication Date
DK2097444T3 true DK2097444T3 (da) 2011-08-29

Family

ID=46846408

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07859364.7T DK2097444T3 (da) 2006-11-24 2007-11-23 Fremgangsmåde, der anvender et transgent dyr med forøget immunrespons

Country Status (12)

Country Link
US (2) US20100041743A1 (da)
EP (3) EP2097444B1 (da)
JP (2) JP5752355B2 (da)
CN (1) CN101595128B (da)
AT (1) ATE513852T1 (da)
AU (2) AU2007323049B2 (da)
CA (1) CA2670389C (da)
DK (1) DK2097444T3 (da)
HK (1) HK1134305A1 (da)
HU (1) HU0700534D0 (da)
PL (1) PL2097444T3 (da)
WO (1) WO2008062383A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102178064B1 (ko) * 2009-12-21 2020-11-12 리제너론 파마슈티칼스 인코포레이티드 인간화된 ＦｃγＲ 마우스
PT2770822T (pt) 2011-10-28 2017-09-18 Regeneron Pharma Ratinhos geneticamente modificados que expressam moléculas quiméricas de complexo principal de histocompatibilidade (mhc) ii
DK2773952T3 (da) * 2011-11-03 2019-04-23 Univ Iowa Res Found Transgene svinemodeller af cystisk fibrose
US10154658B2 (en) * 2013-02-22 2018-12-18 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
WO2015036004A1 (en) * 2013-09-13 2015-03-19 Immunogenes Ag Method for preparing an improved atg composition
CN104237533A (zh) * 2014-09-23 2014-12-24 中国科学院东北地理与农业生态研究所 一种初步筛选可用于繁殖后代转基因母羊的方法
US20240081301A1 (en) * 2021-02-02 2024-03-14 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric fcrn
CN116076438B (zh) * 2023-03-21 2024-01-30 湖南中医药大学 类风湿关节炎合并间质性肺病动物模型及其构建方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2690956B2 (ja) 1987-08-22 1997-12-17 三井東圧化学株式会社 生体由来のタンパク質
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5675063A (en) * 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1999013092A1 (en) * 1997-09-11 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Enhancement of mucosal antibody responses by interleukin-6
US6249816B1 (en) * 1998-07-22 2001-06-19 Nokia Telecommunications, Oy NBR pool for SIMA network
US7074983B2 (en) 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
CA2399561A1 (en) * 2000-02-03 2001-08-09 Lennart Hammarstrom Ruminant mhc class i-like fc receptors
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
WO2002043658A2 (en) * 2000-11-06 2002-06-06 The Jackson Laboratory Fcrn-based therapeutics for the treatment of auto-immune disorders
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
CA2559144C (en) 2004-03-10 2014-01-21 Creighton University Estrogen receptor alpha splice variant er-.alpha.36
CN103710371B (zh) 2005-08-03 2017-03-01 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
EP1790716A1 (en) 2005-11-23 2007-05-30 UMC Utrecht Holding B.V. Uses of the FcRn receptor

Also Published As

Publication number Publication date
EP2097444A2 (en) 2009-09-09
US20100041743A1 (en) 2010-02-18
CA2670389C (en) 2014-12-09
EP2559701B1 (en) 2016-04-20
HK1134305A1 (en) 2010-04-23
AU2007323049A8 (en) 2011-07-28
CA2670389A1 (en) 2008-05-29
EP2559701A1 (en) 2013-02-20
JP2010510773A (ja) 2010-04-08
CN101595128A (zh) 2009-12-02
ATE513852T1 (de) 2011-07-15
JP2013215194A (ja) 2013-10-24
WO2008062383A3 (en) 2008-08-14
WO2008062383A2 (en) 2008-05-29
HU0700534D0 (en) 2007-10-29
CN101595128B (zh) 2014-11-26
EP2386573A1 (en) 2011-11-16
AU2007323049A1 (en) 2008-05-29
AU2012203243A1 (en) 2012-06-21
AU2007323049B2 (en) 2012-03-15
PL2097444T3 (pl) 2011-11-30
US20130109087A1 (en) 2013-05-02
EP2097444B1 (en) 2011-06-22
JP5752355B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
HK1134305A1 (en) Method using a transgenic animal with enhanced immune response
WO2007117410A3 (en) Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
SG10201408500RA (en) Antibody producing non-human mammals
DK2152880T3 (da) Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer
ES2849349T3 (es) Anticuerpos de cadena ligera modificados mediante ingeniería con histidina y roedores modificados genéticamente para la generación de los mismos
LTPA2017022I1 (lt) Antikūnai prieš Clostridium difficile toksinus ir jų panaudojimas
CY1121223T1 (el) Ποντικοι οι οποιοι εκφραζουν ανθρωποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
ECSP12011698A (es) Anticuerpos cea
BR112014009941A2 (pt) camundongos transgênicos expressando moléculas do complexo de histocompatibilidade principal (mhc) quimérico classe ii
NZ577828A (en) Human antibodies that bind human il-12 and methods for producing
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
AR052285A1 (es) Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas
DK1210374T3 (da) Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
DK1483294T3 (da) Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
HK1118458A1 (en) Anti-il-23 antibodies, compositions, methods and uses
DE69638184D1 (de) Transgene nicht-menschlicher tiere befaehigt zur produktion heterologer antikoerper
BRPI0921665A2 (pt) humanizado anti-il-6 anticorpos
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
MX2007014610A (es) Anticuerpos anti-proteina quimioatrayente de monocitos-1, composiciones, metodos y usos.
ATE519784T1 (de) An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
Kacskovics et al. Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies
DE602005026688D1 (de) Toleranzstudienverfahren bei mhc-ii-transgenen tieren
SG142293A1 (en) Method for producing anti-idiotypic antibodies